Talapo Threrapeutics is at the forefront of cellular approaches to treat obesity. Talapo is developing several new biologic agents to treat obesity. Talapo agents target growth factors with roles in adipogenesis blocking the cellular process of producing fat tissue and inhibiting the storage of fat.
Overweight and obesity are chronic diseases that have a profoundly negative impact on health worldwide. About 35 percent of women and 31 percent of men are considered seriously overweight in the USA. Overweight and obesity-related conditions cause an estimated 325,000 premature deaths and cost over 150 billion dollars each year in the U.S. alone. Increased health risks associated with obesity include hypertension, type 2 diabetes, cardiovascular diseases, and cancers. The U.S. Surgeon General has declared that the “epidemic of overweight and obesity threatens the historic progress we have made in increasing American’s quality and years of healthy life”. As obesity is associated with serious complications such as Nonalcoholic steatohepatitis (NASH), and type 2 diabetes (T2D), developing safe and effective anti-obesity treatments is a global priority.
Possible treatments include lifestyle changes, weight-loss surgery, and pharmacotherapy. Dietary and lifestyle changes are effective but difficult to maintain long-term. Weight loss surgery is an option for treating adults and teenagers with severe obesity and related health problems such as type 2 diabetes, and high blood pressure, but these procedures are invasive, expensive and associated with major health risks. Pharmacological approaches for treating obesity also exist. Most FDA approved weight-loss therapeutics suppress appetite or caloric intake. However, these agents have a major history of failure due to adverse side effects and limited efficacy. In addition, for patients to maintain weight loss long-term, the metabolic set point must be readjusted, likely by reducing the number of adipocytes in the body. But pharmacological approaches that target the cellular process of producing adipose tissue or regulating fat storage do not exist. Clearly, the current state of anti-obesity therapies is inadequate, revealing a critical need for effective pharmacological treatments that ameliorate or reverse the obese phenotype and improve obesity related co-morbidities.